AbCellera Biologics Inc. (ABCL) income statement
NASDAQ · Healthcare · Biotechnology · 562 employees · CEO Carl Hansen
- Price
- $12.27 -6.19%
- Market cap
- $3.98B
- Enterprise value
- $3.99B
- Last report
- Q2 '26 filed 2026-08-05
- Next report
- 2026-11-09
AbCellera Biologics Inc. (ABCL) reported revenue of $4.05M for Q2 '26 (-76.3% year on year), operating income of -$62.8M (-1,550.0% of revenue) and net income of -$55.4M. Over the last four quarters revenue was $66.2M.
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.6M | $9.18M | $9.95M | $7.32M | $6.51M | $5.05M | $4.24M | $17.1M | $8.96M | $44.9M | $8.32M | $4.05M | |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $7.92M | $8.66M | $0 | |
| Gross profit | $6.6M | $9.18M | $9.95M | $7.32M | $6.51M | $5.05M | $4.24M | $17.1M | $8.96M | $36.9M | -$340K | $4.05M | |
| Research & development | $37.9M | $48.6M | $39.3M | $40.9M | $41M | $46.1M | $42.5M | $39.2M | $55M | $50.1M | $46.7M | $46M | |
| Sales & marketing | $3.47M | $3.1M | $3.37M | $3.14M | $3.14M | $3.14M | $2.84M | $3.01M | $2.91M | $0 | $0 | $0 | |
| General & administrative | $14.4M | $16M | $17.4M | $20.2M | $19.1M | $16M | $16.2M | $19M | $22.1M | $0 | $0 | $0 | |
| Other operating expenses | $5.74M | $7.54M | $4.84M | $36.5M | $36.9M | $12.6M | $5.33M | $5.47M | $5.25M | $0 | $0 | $6.99M | |
| Operating expenses | $61.5M | $75.2M | $64.8M | $101M | $100M | $77.8M | $66.9M | $66.7M | $85.2M | $65.5M | $57.2M | $66.8M | |
| Operating income | -$54.9M | -$66.1M | -$54.9M | -$93.5M | -$93.7M | -$72.8M | -$62.7M | -$49.6M | -$76.3M | -$28.6M | -$57.5M | -$62.8M | |
| Interest income | $10.7M | $11M | $10.4M | $9.8M | $9.6M | $8.67M | $8.05M | $7.59M | $6.77M | $5.92M | $3.64M | $0 | |
| Other non-operating income (gains on investments, FX ...) | -$2.83M | -$3.38M | -$3.28M | -$3.31M | -$3.49M | -$3.54M | -$4.15M | -$3.69M | -$2.73M | -$9.08M | -$7.98M | -$3.81M | |
| Total non-operating income | $15.6M | $17.5M | $12.1M | $45.3M | $31M | $25.9M | $9.68M | $13.2M | $7.51M | $9.08M | $7.98M | $3.81M | |
| Income before tax | -$39.3M | -$48.6M | -$42.7M | -$48.2M | -$62.6M | -$46.8M | -$53M | -$36.3M | -$68.8M | -$19.5M | -$49.5M | -$59M | |
| Income tax | -$10.7M | -$1.45M | -$2.14M | -$11.3M | -$11.5M | -$12.6M | -$7.36M | -$1.62M | -$11.6M | -$10.6M | -$6.37M | -$3.54M | |
| Net income | -$28.6M | -$47.2M | -$40.6M | -$36.9M | -$51.1M | -$34.2M | -$45.6M | -$34.7M | -$57.1M | -$8.95M | -$43.2M | -$55.4M | |
| EPS (basic) | -$0.10 | -$0.16 | -$0.14 | -$0.13 | -$0.17 | -$0.12 | -$0.15 | -$0.12 | -$0.19 | -$0.03 | -$0.14 | -$0.18 | |
| EPS (diluted) | -$0.10 | -$0.16 | -$0.14 | -$0.13 | -$0.17 | -$0.12 | -$0.15 | -$0.12 | -$0.19 | -$0.03 | -$0.14 | -$0.18 | |
| Shares (basic, weighted) | 289M | 291M | 293M | 294M | 295M | 295M | 298M | 299M | 299M | 299M | 303M | 306M | |
| Shares (diluted, weighted) | 289M | 291M | 293M | 294M | 295M | 295M | 298M | 299M | 299M | 299M | 303M | 306M | |
| Depreciation & amortization | $7.41M | $9.11M | $6.77M | $38M | $38.3M | $13.9M | $6.61M | $7.06M | $7.24M | $7.92M | $8.66M | $8.78M | |
| EBITDA | -$44.7M | -$53.6M | -$44.9M | -$52.1M | -$51.9M | -$55.3M | -$51.9M | -$38.8M | -$66.3M | -$11.6M | -$40.9M | -$50.2M |
| Income statement | Trend | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.83M | $11.6M | $233M | $375M | $485M | $38M | $28.8M | $75.1M | |
| Cost of revenue | $0 | $0 | $27.1M | $45.5M | $66.4M | $0 | $0 | $28.8M | |
| Gross profit | $8.83M | $11.6M | $206M | $330M | $419M | $38M | $28.8M | $46.3M | |
| Research & development | $5.8M | $10.1M | $29.4M | $62.1M | $108M | $176M | $167M | $187M | |
| Sales & marketing | $712K | $1.26M | $3.84M | $6.91M | $11.3M | $14.2M | $12.8M | $0 | |
| General & administrative | $2.15M | $2.75M | $11.9M | $41.8M | $55.5M | $61M | $72.7M | $0 | |
| Other operating expenses | $918K | $1.6M | $4.84M | $14.5M | $27.8M | $24.4M | $90.9M | $0 | |
| Operating expenses | $9.58M | $15.7M | $50M | $125M | $202M | $275M | $344M | $263M | |
| Operating income | -$753K | -$4.12M | $156M | $204M | $217M | -$237M | -$315M | -$217M | |
| Interest income | $42K | $155K | $293K | $3.33M | $16.1M | $42.2M | $38.5M | $28.3M | |
| Interest expense | $212K | $209K | $6.51M | $5.23M | $4.05M | $0 | $0 | $0 | |
| Other non-operating income (gains on investments, FX ...) | -$1.27M | -$2.12M | -$8.31M | -$17.5M | -$10.6M | -$14.2M | -$13.6M | -$39.5M | |
| Total non-operating income | $1.06M | $1.91M | $1.8M | $14.7M | $22.6M | $63.2M | $114M | $39.5M | |
| Income before tax | $309K | -$2.21M | $158M | $219M | $239M | -$174M | -$200M | -$178M | |
| Income tax | $0 | $0 | $38.9M | $65.7M | $80.6M | -$27.6M | -$37.5M | -$31.2M | |
| Net income | $309K | -$2.21M | $119M | $153M | $159M | -$146M | -$163M | -$146M | |
| EPS (basic) | $0.00 | -$0.01 | $0.45 | $0.56 | $0.56 | -$0.51 | -$0.55 | -$0.49 | |
| EPS (diluted) | $0.00 | -$0.01 | $0.45 | $0.48 | $0.50 | -$0.51 | -$0.55 | -$0.49 | |
| Shares (basic, weighted) | 151M | 215M | 263M | 276M | 285M | 289M | 294M | 299M | |
| Shares (diluted, weighted) | 151M | 238M | 263M | 318M | 315M | 289M | 294M | 299M | |
| Depreciation & amortization | $918K | $1.85M | $5.27M | $17.3M | $33.1M | $30.9M | $97M | $28.8M | |
| EBITDA | $1.44M | -$155K | $170M | $239M | $260M | -$192M | -$204M | -$149M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02